search
Back to results

Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers

Primary Purpose

Pneumonia, Pneumococcal

Status
Completed
Phase
Phase 1
Locations
Kenya
Study Type
Interventional
Intervention
PATH-wSP
Synflorix
Pentavac
Saline
Sponsored by
PATH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pneumonia, Pneumococcal

Eligibility Criteria

12 Months - 45 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy young Kenyan adults between 18 to 45 years of age
  • Willing to provide written informed consent, able to understand comply with study requirements/procedures.
  • Adult female subjects surgically sterilized or with a negative serum pregnancy test on enrollment and prior to each vaccination. Adult females must be willing to avoid becoming pregnant over the duration of the study, and must agree to employ an effective form of birth control for the duration of the study.
  • Subjects willing to avoid consumption of herbal medication (including herbal medication taken by a mother, which may transmit to a toddler through breast milk) that could have effects on liver function or bleeding indices during the course of the study.
  • Healthy toddlers between 12 to 15 months of age who have completed their primary EPI vaccines.
  • Toddler's parent willing to provide written informed consent for subject, able to understand and comply with study requirements and procedures.
  • Not premature, had a birth weight of >2.5 kg, and a weight-to-height Z score of ≥ -2 at the time of enrollment.

Exclusion Criteria:

  • Use of any investigational or nonregistered drug within 90 days prior and during the course of study participation.
  • History of administration of any vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study.
  • History of anaphylactic shock.
  • Positive test for malaria (blood film) at time of screening and when retested at Visit 1.
  • Immunosuppression or immunodeficiency, inclusive of human immunodeficiency virus, by medical history or by testing at screening.
  • Chronic, clinically significant pulmonary, cardiovascular, hepatobiliary, gastrointestinal, renal, neurological, or hematological functional abnormality or major congenital defects or illness that requires medical therapy, as deemed by medical history or clinical assessment.
  • Evidence of active hepatitis infection (B or C) by immunologic testing at screening.
  • Any medical or social condition that in the opinion of the investigator will interfere with the study objectives or pose a risk to the study subject or may prevent the subject from completing the study follow-up.
  • An employee (or first degree relative of employee) of the Sponsor, the Clinical Research Organization, or any investigator or site personnel.
  • Any screening laboratory test result or vital sign measurement outside normal parameters and deemed by the clinician to be clinically significant, including a positive test for malaria.
  • Acute illness (moderate or severe) and/or fever (tympanic temperature >38°C for adults and >37.5°C for toddlers), or any acute and limited illness requiring medical treatment, including the use of antibiotics and treatment for parasites.
  • History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
  • Disorders that require chronic administration of immune-modifying drugs within the past 6 months prior to the administration of the study vaccine.
  • Administration of immunoglobulins and/or any blood products within the 6 months preceding enrollment in the study; or anticipation of such administration during the study period.
  • Known disturbance of coagulation or other blood disorder in adult subject or in self/first degree relative of toddler subject; or receipt of anticoagulants in the past 3 weeks.
  • History of meningitis or seizures or any neurological disorder or major psychiatric disorder (adult).
  • Female subjects who are pregnant or breast-feeding.
  • Suspicion or recent history of alcohol or substance abuse.
  • Toddlers with evidence of congenital abnormality or developmental delay.
  • Toddlers with evidence of fetal alcohol syndrome or history of alcohol abuse in mother during pregnancy.
  • Toddlers exposed to HIV, born of an HIV infected mother, or who are HIV positive by either antibody or polymerase chain reaction testing.

Sites / Locations

  • Kenya Medical Research Institute/Walter Reed Project

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Experimental

Active Comparator

Experimental

Experimental

Active Comparator

Arm Label

Adult Cohort 1, PATH-wSP, 600 mcg

Adult Cohort 1, Saline

Adult Cohort 2, PATH-wSP, 1000 mcg

Adult Cohort 2, Saline

Toddler Cohort 1 PATH-wSP 300 mcg+Active control

Toddler Cohort 1 PATH-wSP 300 mcg+Saline

Toddler Cohort 1: Active Control Only

Toddler Cohort 2 PATH-wSP 600 mcg+Active control

Toddler Cohort 2 PATH-wSP 600 mcg+saline

Toddler Cohort 2: Active Control Only

Arm Description

A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.

A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.

A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.

A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.

A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.

A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.

A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.

A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.

A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.

A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.

Outcomes

Primary Outcome Measures

Number/Percent of Adult Subjects Experiencing Fatigue/Malaise Following Vaccination
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Number/Percent of Adult Subjects Experiencing Myalgia Following Vaccination
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Number/Percent of Adult Subjects Experiencing Headache Following Vaccination
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Grade 2 includes repeated use of non-narcotic pain reliever for more than 24 hours.
Number/Percent of Adult Subjects Experiencing Pain at Injection Site Following Vaccination
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Grade 2 includes use of non-narcotic pain reliever for more than 24 hours.
Number/Percent of Adult Subjects Experiencing Tenderness at Injection Site Following Vaccination
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Number/Percent of Adult Subjects Experiencing Induration at Injection Site Following Vaccination
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Grade 1: does not interfere with activity Grade 2: interferes with activity
Number/Percent of Adult Subjects Experiencing Fever at Injection Site Following Vaccination
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Number/Percent of Toddler Subjects Experiencing Fever Following Vaccination
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Number/Percent of Toddler Subjects Experiencing Cutaneous Rash Following Vaccination
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Grade 2: includes diffuse macular/maculopapular/morbilliform rash
Number/Percent of Toddler Subjects Experiencing Irritability Following Vaccination
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).
Number/Percent of Toddler Subjects Experiencing Drowsiness Following Vaccination
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).
Number/Percent of Toddler Subjects Experiencing Loss of Appetite Following Vaccination
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).
Number/Percent of Toddler Subjects Experiencing Pain/Tenderness at Injection Site Following Vaccination
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Number/Percent of Toddler Subjects Experiencing Induration/Swelling at Injection Site Following Vaccination
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).

Secondary Outcome Measures

Geometric Mean Concentrations (GMC) of IgG Antibodies Against Pneumolysoid (L460D) Pneumococcal Protein: ELISA Assay
Measured with enzyme-linked immunosorbent assay (ELISA).
Geometric Mean Concentrations (GMC) of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: ELISA Assay
Measured with enzyme-linked immunosorbent assay (ELISA).
Geometric Mean Concentrations (GMC) of IgG Antibodies Against L460D Pneumococcal Protein
Measured using meso scale discovery (MSD).
Geometric Mean Concentrations (GMC) of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: Meso Scale Discovery (MSD) Assay
Geometric Mean Concentrations (GMC) of IgG Antibodies Against PhtD Pneumococcal Protein
Measured using Meso Scale Discovery (MSD) Assay
Geometric Mean Concentrations (GMC) of IgG Antibodies Against BCH0785 Pneumococcal Protein
Measured using Meso Scale Discovery (MSD) Assay
Geometric Mean Concentrations (GMC) of IgG Antibodies Against StkP Pneumococcal Protein
Measured using Meso Scale Discovery (MSD) Assay
Geometric Mean Concentrations (GMC) of IgG Antibodies Against PcpA Pneumococcal Protein
Measured using Meso Scale Discovery (MSD) Assay
Geometric Mean Concentrations (GMC) of IgG Antibodies Against SPWCA Pneumococcal Protein
MSD Assay
Geometric Mean Concentrations (GMC) of IgG Antibodies Against PiuA Pneumococcal Protein
MSD Assay
Geometric Mean Concentrations (GMC) of IgG Antibodies Against PiaA Pneumococcal Protein
MSD Assay
Geometric Mean Fold Change of IgG Antibodies Against Pneumolysoid (L460D) Pneumococcal Protein: ELISA
Measured using ELISA
Geometric Mean Fold Change of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: ELISA
Measured using ELISA
Geometric Mean Fold Change of IgG Antibodies Against Pneumolysoid (L460D) Pneumococcal Protein: MSD
Measured using MSD
Geometric Mean Fold Change of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: MSD
Measured using ELISA
Geometric Mean Fold Change of IgG Antibodies Against PhtD Pneumococcal Protein
Measured using MSD
Geometric Mean Fold Change of IgG Antibodies Against BCH0785 Pneumococcal Protein
Measured using MSD
Geometric Mean Fold Change of IgG Antibodies Against StkP Pneumococcal Protein
Measured using MSD
Geometric Mean Fold Change of IgG Antibodies Against PcpA Pneumococcal Protein
Measured using MSD
Geometric Mean Fold Change of IgG Antibodies Against SPWCA Pneumococcal Protein
Measured using MSD
Geometric Mean Fold Change of IgG Antibodies Against PiuA Pneumococcal Protein
Measured using MSD
Geometric Mean Fold Change of IgG Antibodies Against PiaA Pneumococcal Protein
Measured using MSD
Fold Change in IgG Response to Pneumolysoid (L460D) Pneumococcal Protein Among Toddler Cohort (ELISA)
Measured using ELISA
Fold Change in IgG Response to PspA-Fam1 (ELISA)
Measured using ELISA
Fold Change in IgG Response to L460D Pneumococcal Protein (MSD)
Measured using MSD
Fold Change in IgG Response to PspA-Fam1 Pneumococcal Protein (MSD)
Measured using MSD
Fold Change in IgG Response to PhtD Pneumococcal Protein
Measured using MSD
Fold Change in IgG Response to BCH0785 Pneumococcal Protein
Measured using MSD
Fold Change in IgG Response to StkP Pneumococcal Protein
Measured using MSD
Fold Change in IgG Response to PcpA Pneumococcal Protein
Measured using MSD
Fold Change in IgG Response to SPWCA Pneumococcal Protein
Measured using MSD
Fold Change in IgG Response to PiuA Pneumococcal Protein
Measured using MSD
Fold Change in IgG Response to PiaA Pneumococcal Protein
Measured using MSD
Number/Percentage of Adult Subjects With Neutralizing Antibody Response to Pneumolysin
Functional antibody responses to Ply (pneumolysin) were assessed using a toxin neutralization assay based on the ability of antibodies to neutralize wild-type Ply-induced lysis of rabbit red blood cells. Briefly, serial 2-fold dilutions (starting at 1/5 dilution) of human serum samples were added together with wild-type Ply in 96-well plates. Rabbit red blood cells were then added and following incubation supernatants removed and transferred to new 96-well plates and absorbance measured at 540 nm using a spectrophotometer plate reader. The mean A450 nm blank value was subtracted by 10% to obtain the Plate Specific Cut Point for each plate. Each sample was categorized as negative (<1/20) or positive (with titer between 1/20 and 1/320).
Number/Percentage of Toddler Subjects With Neutralizing Antibody Response to Pneumolysin
Functional antibody responses to Ply (pneumolysin) were assessed using a toxin neutralization assay based on the ability of antibodies to neutralize wild-type Ply-induced lysis of rabbit red blood cells. Briefly, serial 2-fold dilutions (starting at 1/5 dilution) of human serum samples were added together with wild-type Ply in 96-well plates. Rabbit red blood cells were then added and following incubation supernatants removed and transferred to new 96-well plates and absorbance measured at 540 nm using a spectrophotometer plate reader. The mean A450 nm blank value was subtracted by 10% to obtain the Plate Specific Cut Point for each plate. Each sample was categorized as negative (<1/20) or positive (with titer between 1/20 and 1/320).

Full Information

First Posted
March 17, 2014
Last Updated
October 1, 2019
Sponsor
PATH
search

1. Study Identification

Unique Protocol Identification Number
NCT02097472
Brief Title
Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers
Official Title
A Dose-Finding Study to Assess the Safety, Tolerability, and Immunogenicity of Inactivated Streptococcus Pneumoniae Whole Cell Vaccine Formulated With Alum (PATH-wSP) in Healthy Kenyan Young Adults and PCV-Primed Toddlers
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
April 2014 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
PATH

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to assess the safety and tolerability of PATH-wSP, administered intramuscularly to healthy Kenyan adults and toddlers who have been primed with a pneumococcal conjugate vaccine (PCV). Additionally, the study will explore whether a measurable immune response is elicited when PATH-wSP is administered to healthy Kenyan adults and toddlers who have been primed with PCV.
Detailed Description
S. pneumoniae whole cell vaccine (SPWCV) is a vaccine candidate made from whole, unencapsulated pneumococcal cells. S. pneumoniae whole cell antigen bulk was manufactured at Walter Reed Army Institute of Research from strain RM200 RX1E PdT ΔlytA and is inactivated with beta-propiolactone. Pneumolysin, a proven virulence factor, was genetically knocked out in SPWCV and replaced with pneumolysoid, a derivative carrying the toxin gene with 3 point mutations known to abolish both cytolytic activity and complement activation. When adsorbed to aluminum hydroxide (alum), SPWCV is utilized as the vaccine candidate Streptococcus pneumoniae whole cell vaccine with aluminum hydroxide adjuvant (PATH-wSP) for clinical investigation. PATH-wSP has been previously tested in adults in a Phase 1 trial in the US, in which doses of 100 to 600 μg were given to healthy young adults in a 3-vaccination series and showed a favorable safety, tolerability, and immunogenicity profile. This study was a dose escalation and age de-escalation study, and sequential cohorts of subjects were identified to allow safety evaluations of dosing and ages to occur progressively during the study. The following PATH-wSP cohorts were defined for adult and toddler subjects: Adult Cohort 1: 600 μg PATH-wSP or saline Adult Cohort 2: 1000 μg PATH-wSP or saline Toddler Cohort 1: 300 μg PATH-wSP and/or active control vaccines Toddler Cohort 2: 600 μg PATH-wSP and/or active control vaccines.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pneumonia, Pneumococcal

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
304 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Adult Cohort 1, PATH-wSP, 600 mcg
Arm Type
Experimental
Arm Description
A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.
Arm Title
Adult Cohort 1, Saline
Arm Type
Placebo Comparator
Arm Description
A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.
Arm Title
Adult Cohort 2, PATH-wSP, 1000 mcg
Arm Type
Experimental
Arm Description
A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.
Arm Title
Adult Cohort 2, Saline
Arm Type
Placebo Comparator
Arm Description
A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.
Arm Title
Toddler Cohort 1 PATH-wSP 300 mcg+Active control
Arm Type
Experimental
Arm Description
A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
Arm Title
Toddler Cohort 1 PATH-wSP 300 mcg+Saline
Arm Type
Experimental
Arm Description
A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
Arm Title
Toddler Cohort 1: Active Control Only
Arm Type
Active Comparator
Arm Description
A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
Arm Title
Toddler Cohort 2 PATH-wSP 600 mcg+Active control
Arm Type
Experimental
Arm Description
A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
Arm Title
Toddler Cohort 2 PATH-wSP 600 mcg+saline
Arm Type
Experimental
Arm Description
A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
Arm Title
Toddler Cohort 2: Active Control Only
Arm Type
Active Comparator
Arm Description
A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
Intervention Type
Biological
Intervention Name(s)
PATH-wSP
Intervention Description
Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
Intervention Type
Biological
Intervention Name(s)
Synflorix
Other Intervention Name(s)
10-valent Pneumococcal Conjugate Vaccine (PCV10)
Intervention Description
1 dose (0.5 mL) contains: 1 μg of each of the following pneumococcal polysaccharide serotypes: 1, 5, 6B, 7F, 9V, 14, and 23 F And 3 μg of the following pneumococcal polysaccharide serotypes: 4, 18C and 19F. The serotypes are conjugated to either: protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein
Intervention Type
Biological
Intervention Name(s)
Pentavac
Other Intervention Name(s)
Diptheria Pertussis Tetanus Hep B Haemophilus b Conjugate
Intervention Description
Each PFS contains 0.5 ml (single dose): Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 % Dose: O.5ml by intramuscular injection.
Intervention Type
Other
Intervention Name(s)
Saline
Intervention Description
0.9% Sodium Chloride Injection, USP
Primary Outcome Measure Information:
Title
Number/Percent of Adult Subjects Experiencing Fatigue/Malaise Following Vaccination
Description
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Time Frame
up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)
Title
Number/Percent of Adult Subjects Experiencing Myalgia Following Vaccination
Description
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Time Frame
up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)
Title
Number/Percent of Adult Subjects Experiencing Headache Following Vaccination
Description
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Grade 2 includes repeated use of non-narcotic pain reliever for more than 24 hours.
Time Frame
up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)
Title
Number/Percent of Adult Subjects Experiencing Pain at Injection Site Following Vaccination
Description
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Grade 2 includes use of non-narcotic pain reliever for more than 24 hours.
Time Frame
up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)
Title
Number/Percent of Adult Subjects Experiencing Tenderness at Injection Site Following Vaccination
Description
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Time Frame
up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)
Title
Number/Percent of Adult Subjects Experiencing Induration at Injection Site Following Vaccination
Description
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Grade 1: does not interfere with activity Grade 2: interferes with activity
Time Frame
up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)
Title
Number/Percent of Adult Subjects Experiencing Fever at Injection Site Following Vaccination
Description
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Time Frame
up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)
Title
Number/Percent of Toddler Subjects Experiencing Fever Following Vaccination
Description
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Time Frame
up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)
Title
Number/Percent of Toddler Subjects Experiencing Cutaneous Rash Following Vaccination
Description
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Grade 2: includes diffuse macular/maculopapular/morbilliform rash
Time Frame
up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)
Title
Number/Percent of Toddler Subjects Experiencing Irritability Following Vaccination
Description
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).
Time Frame
up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)
Title
Number/Percent of Toddler Subjects Experiencing Drowsiness Following Vaccination
Description
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).
Time Frame
up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)
Title
Number/Percent of Toddler Subjects Experiencing Loss of Appetite Following Vaccination
Description
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).
Time Frame
up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)
Title
Number/Percent of Toddler Subjects Experiencing Pain/Tenderness at Injection Site Following Vaccination
Description
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination.
Time Frame
up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)
Title
Number/Percent of Toddler Subjects Experiencing Induration/Swelling at Injection Site Following Vaccination
Description
Solicited reactions were assessed for severity during the 60 minutes post vaccination time period, daily for the first week by Field Staff and then at the clinic visit 1 week post vaccination. Severity was defined in the protocol as grade 0-4 (none, mild, moderate, and severe).
Time Frame
up to 1 week following first vaccination (Day 7) or second vaccination (Day 35)
Secondary Outcome Measure Information:
Title
Geometric Mean Concentrations (GMC) of IgG Antibodies Against Pneumolysoid (L460D) Pneumococcal Protein: ELISA Assay
Description
Measured with enzyme-linked immunosorbent assay (ELISA).
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Concentrations (GMC) of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: ELISA Assay
Description
Measured with enzyme-linked immunosorbent assay (ELISA).
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Concentrations (GMC) of IgG Antibodies Against L460D Pneumococcal Protein
Description
Measured using meso scale discovery (MSD).
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Concentrations (GMC) of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: Meso Scale Discovery (MSD) Assay
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Concentrations (GMC) of IgG Antibodies Against PhtD Pneumococcal Protein
Description
Measured using Meso Scale Discovery (MSD) Assay
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Concentrations (GMC) of IgG Antibodies Against BCH0785 Pneumococcal Protein
Description
Measured using Meso Scale Discovery (MSD) Assay
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Concentrations (GMC) of IgG Antibodies Against StkP Pneumococcal Protein
Description
Measured using Meso Scale Discovery (MSD) Assay
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Concentrations (GMC) of IgG Antibodies Against PcpA Pneumococcal Protein
Description
Measured using Meso Scale Discovery (MSD) Assay
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Concentrations (GMC) of IgG Antibodies Against SPWCA Pneumococcal Protein
Description
MSD Assay
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Concentrations (GMC) of IgG Antibodies Against PiuA Pneumococcal Protein
Description
MSD Assay
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Concentrations (GMC) of IgG Antibodies Against PiaA Pneumococcal Protein
Description
MSD Assay
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Fold Change of IgG Antibodies Against Pneumolysoid (L460D) Pneumococcal Protein: ELISA
Description
Measured using ELISA
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Fold Change of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: ELISA
Description
Measured using ELISA
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Fold Change of IgG Antibodies Against Pneumolysoid (L460D) Pneumococcal Protein: MSD
Description
Measured using MSD
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Fold Change of IgG Antibodies Against PspA-Fam1 Pneumococcal Protein: MSD
Description
Measured using ELISA
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Fold Change of IgG Antibodies Against PhtD Pneumococcal Protein
Description
Measured using MSD
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Fold Change of IgG Antibodies Against BCH0785 Pneumococcal Protein
Description
Measured using MSD
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Fold Change of IgG Antibodies Against StkP Pneumococcal Protein
Description
Measured using MSD
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Fold Change of IgG Antibodies Against PcpA Pneumococcal Protein
Description
Measured using MSD
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Fold Change of IgG Antibodies Against SPWCA Pneumococcal Protein
Description
Measured using MSD
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Fold Change of IgG Antibodies Against PiuA Pneumococcal Protein
Description
Measured using MSD
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Geometric Mean Fold Change of IgG Antibodies Against PiaA Pneumococcal Protein
Description
Measured using MSD
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Fold Change in IgG Response to Pneumolysoid (L460D) Pneumococcal Protein Among Toddler Cohort (ELISA)
Description
Measured using ELISA
Time Frame
28 days (post-vaccination 1) and 56 days (post-vaccination 2)
Title
Fold Change in IgG Response to PspA-Fam1 (ELISA)
Description
Measured using ELISA
Time Frame
28 days (post-vaccination 1) and 56 days (post-vaccination 2)
Title
Fold Change in IgG Response to L460D Pneumococcal Protein (MSD)
Description
Measured using MSD
Time Frame
28 days (post-vaccination 1) and 56 days (post-vaccination 2)
Title
Fold Change in IgG Response to PspA-Fam1 Pneumococcal Protein (MSD)
Description
Measured using MSD
Time Frame
28 days (post-vaccination 1) and 56 days (post-vaccination 2)
Title
Fold Change in IgG Response to PhtD Pneumococcal Protein
Description
Measured using MSD
Time Frame
28 days (post-vaccination 1) and 56 days (post-vaccination 2)
Title
Fold Change in IgG Response to BCH0785 Pneumococcal Protein
Description
Measured using MSD
Time Frame
28 days (post-vaccination 1) and 56 days (post-vaccination 2)
Title
Fold Change in IgG Response to StkP Pneumococcal Protein
Description
Measured using MSD
Time Frame
28 days (post-vaccination 1) and 56 days (post-vaccination 2)
Title
Fold Change in IgG Response to PcpA Pneumococcal Protein
Description
Measured using MSD
Time Frame
28 days (post-vaccination 1) and 56 days (post-vaccination 2)
Title
Fold Change in IgG Response to SPWCA Pneumococcal Protein
Description
Measured using MSD
Time Frame
28 days (post-vaccination 1) and 56 days (post-vaccination 2)
Title
Fold Change in IgG Response to PiuA Pneumococcal Protein
Description
Measured using MSD
Time Frame
28 days (post-vaccination 1) and 56 days (post-vaccination 2)
Title
Fold Change in IgG Response to PiaA Pneumococcal Protein
Description
Measured using MSD
Time Frame
28 days (post-vaccination 1) and 56 days (post-vaccination 2)
Title
Number/Percentage of Adult Subjects With Neutralizing Antibody Response to Pneumolysin
Description
Functional antibody responses to Ply (pneumolysin) were assessed using a toxin neutralization assay based on the ability of antibodies to neutralize wild-type Ply-induced lysis of rabbit red blood cells. Briefly, serial 2-fold dilutions (starting at 1/5 dilution) of human serum samples were added together with wild-type Ply in 96-well plates. Rabbit red blood cells were then added and following incubation supernatants removed and transferred to new 96-well plates and absorbance measured at 540 nm using a spectrophotometer plate reader. The mean A450 nm blank value was subtracted by 10% to obtain the Plate Specific Cut Point for each plate. Each sample was categorized as negative (<1/20) or positive (with titer between 1/20 and 1/320).
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Title
Number/Percentage of Toddler Subjects With Neutralizing Antibody Response to Pneumolysin
Description
Functional antibody responses to Ply (pneumolysin) were assessed using a toxin neutralization assay based on the ability of antibodies to neutralize wild-type Ply-induced lysis of rabbit red blood cells. Briefly, serial 2-fold dilutions (starting at 1/5 dilution) of human serum samples were added together with wild-type Ply in 96-well plates. Rabbit red blood cells were then added and following incubation supernatants removed and transferred to new 96-well plates and absorbance measured at 540 nm using a spectrophotometer plate reader. The mean A450 nm blank value was subtracted by 10% to obtain the Plate Specific Cut Point for each plate. Each sample was categorized as negative (<1/20) or positive (with titer between 1/20 and 1/320).
Time Frame
0 days, 28 days (Dose 1) and 56 days (Dose 2)
Other Pre-specified Outcome Measures:
Title
Geometric Mean Concentration (GMCs) of PNC-IgG Serotypes Among Toddler Subjects
Description
GMCs of these IgG proteins were measured to assess potential interference of PATH-wSP with 10-valent pneumococcal conjugate vaccine (Synflorix). GMCs of Cohort 1 were measured at a different time point than those in Cohort 2, so results are presented separately.
Time Frame
12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1
Title
Geometric Mean Concentration (GMC) Ratio of Diptheria Booster Immune Response Among Toddler Subjects
Description
GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.
Time Frame
12 weeks post vaccination 1
Title
Geometric Mean Concentration (GMC) Ratio of Hepatitis B Booster Immune Response Among Toddler Subjects
Description
GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.
Time Frame
12 weeks post vaccination 1
Title
Geometric Mean Concentration (GMC) Ratio of Haemophilus Influenzae Type b (Hib) Booster Immune Response Among Toddler Subjects
Description
GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.
Time Frame
12 weeks post vaccination 1
Title
Geometric Mean Concentration (GMC) Ratio of Pertussis FHA and Pertussis Toxin Immune Response Among Toddler Subjects
Description
GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.
Time Frame
12 weeks post vaccination 1
Title
Geometric Mean Concentration (GMC) Ratio of Pertussis Fimbriae Immune Response Among Toddler Subjects
Description
GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.
Time Frame
12 weeks post vaccination 1
Title
Geometric Mean Concentration (GMC) Ratio of Tetanus Booster Immune Response Among Toddler Subjects
Description
GMCs of these proteins were measured to assess potential interference of PATH-wSP with Pentavac booster dose.
Time Frame
12 weeks post vaccination 1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Months
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy young Kenyan adults between 18 to 45 years of age Willing to provide written informed consent, able to understand comply with study requirements/procedures. Adult female subjects surgically sterilized or with a negative serum pregnancy test on enrollment and prior to each vaccination. Adult females must be willing to avoid becoming pregnant over the duration of the study, and must agree to employ an effective form of birth control for the duration of the study. Subjects willing to avoid consumption of herbal medication (including herbal medication taken by a mother, which may transmit to a toddler through breast milk) that could have effects on liver function or bleeding indices during the course of the study. Healthy toddlers between 12 to 15 months of age who have completed their primary EPI vaccines. Toddler's parent willing to provide written informed consent for subject, able to understand and comply with study requirements and procedures. Not premature, had a birth weight of >2.5 kg, and a weight-to-height Z score of ≥ -2 at the time of enrollment. Exclusion Criteria: Use of any investigational or nonregistered drug within 90 days prior and during the course of study participation. History of administration of any vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study. History of anaphylactic shock. Positive test for malaria (blood film) at time of screening and when retested at Visit 1. Immunosuppression or immunodeficiency, inclusive of human immunodeficiency virus, by medical history or by testing at screening. Chronic, clinically significant pulmonary, cardiovascular, hepatobiliary, gastrointestinal, renal, neurological, or hematological functional abnormality or major congenital defects or illness that requires medical therapy, as deemed by medical history or clinical assessment. Evidence of active hepatitis infection (B or C) by immunologic testing at screening. Any medical or social condition that in the opinion of the investigator will interfere with the study objectives or pose a risk to the study subject or may prevent the subject from completing the study follow-up. An employee (or first degree relative of employee) of the Sponsor, the Clinical Research Organization, or any investigator or site personnel. Any screening laboratory test result or vital sign measurement outside normal parameters and deemed by the clinician to be clinically significant, including a positive test for malaria. Acute illness (moderate or severe) and/or fever (tympanic temperature >38°C for adults and >37.5°C for toddlers), or any acute and limited illness requiring medical treatment, including the use of antibiotics and treatment for parasites. History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines. Disorders that require chronic administration of immune-modifying drugs within the past 6 months prior to the administration of the study vaccine. Administration of immunoglobulins and/or any blood products within the 6 months preceding enrollment in the study; or anticipation of such administration during the study period. Known disturbance of coagulation or other blood disorder in adult subject or in self/first degree relative of toddler subject; or receipt of anticoagulants in the past 3 weeks. History of meningitis or seizures or any neurological disorder or major psychiatric disorder (adult). Female subjects who are pregnant or breast-feeding. Suspicion or recent history of alcohol or substance abuse. Toddlers with evidence of congenital abnormality or developmental delay. Toddlers with evidence of fetal alcohol syndrome or history of alcohol abuse in mother during pregnancy. Toddlers exposed to HIV, born of an HIV infected mother, or who are HIV positive by either antibody or polymerase chain reaction testing.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nekoye Otsyula, MD
Organizational Affiliation
Kenya Medical Research Institute/Walter Reed Project
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kenya Medical Research Institute/Walter Reed Project
City
Kisumu
State/Province
Nyanza
ZIP/Postal Code
PO Box 54-40100
Country
Kenya

12. IPD Sharing Statement

Learn more about this trial

Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers

We'll reach out to this number within 24 hrs